Watch our webinar to see how advanced 3D microtumor platforms and ML-driven screening expose tumor microenvironment (TME) vulnerabilities that conventional approaches routinely overlook.
You'll walk away with:
- How a 3D microtumor screen uncovered a p38-dependent tumor–CAF–ECM circuit that standard assays missed entirely
- A noncanonical DDR1/2–p38–GLI1 axis in CAFs and why it's a viable antibody target
- Data showing kinase inhibition + anti-PD-L1 drives CD8⁺ T cell infiltration
- A practical framework for selecting research-grade antibodies for organoid workflows
Dr. Nao Nishida-Aoki
Waseda University